CompEx asthma: a novel composite exacerbation endpoint

Published on August 29, 2019   29 min

Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms

0:00
Hello, I am Carla Da Silva and I work at AstraZeneca as a Senior Principal Medical Scientist. It is my pleasure today to be presenting the recent work performed on CompEx, a novel Composite Exacerbation Endpoint in Asthma to accelerate clinical development.
0:19
The work presented today was funded by AstraZeneca, and I am a full-time employee of AstraZeneca.
0:27
Why are asthma severe exacerbations of importance? They are important since their prevention is a key goal of treatment. To help standardize across clinical trials, The American Thoracic Society and European Respiratory Society have provided a definition of severe exacerbations. These are defined as worsening of symptoms leading to the use of systemic steroids and hospital admission or an emergency room visit because of asthma requiring systemic steroids. As defined, severe exacerbations are rare events with annualized rates ranging from 0.2 exacerbations a year in mild asthmatics, to 1.1 exacerbations a year for severe asthmatics. As a consequence, clinical trials using severe exacerbation as the primary outcome are lengthy and require large sample sizes to have sufficient power to show differences between interventions. That is why they are conventionally not studied until later in 6,12, and sometimes 18-month Phase 3 trials.
Hide

CompEx asthma: a novel composite exacerbation endpoint

Embed in course/own notes